Bernard Siegel - Aging: The Disease, The Cure, The Implications
Bernard Siegel is the full-time Executive Director of the nonprofit Genetics Policy Institute (GPI) based in Palm Beach Gardens, Florida. He received his undergraduate and law degrees from the University of Miami (BA 1972, JD 1975). He is a member of the Florida Bar since 1975. In 2002, Mr. Siegel filed the landmark case seeking a guardian for the alleged clone, "Baby Eve." The case was widely credited for exposing Clonaid , the so-called "human cloning company" as a sham. In 2003, he traded his 30-year courtroom career to found GPI, which leads the global cause in support of stem cell research. He is a recognized policy expert relating to stem cell research, regenerative medicine and cloning. Working with the world #39;s leading stem cell researchers, Mr. Siegel played a pivotal role in protecting the research in the United Nations, which was under the threat of being banned by world treaty. He also works with grassroots activists throughout the United States, educating lawmakers and formulating effective strategies supporting research for cures. Mr. Siegel serves on the board of directors of Americans for Cures and on the advisory boards of the Sabrina Cohen Foundation for Stem Cell Research, The Brooke Ellison Project and Genomics Education Institute. He is a member of the American Society for Bioethics + Humanities. He is a member of the International Society for Stem Cell Research and serves as the co-chair of the ISSCR Governmental Affairs Committee. Mr. Siegel has been ...From:Jeriaska JeriaskaViews:0 0ratingsTime:18:57More inEducation

Go here to see the original:
Bernard Siegel - Aging: The Disease, The Cure, The Implications - Video

Recommendation and review posted by Bethany Smith

TSG 217 - Transphobia, and the Non-Participation Option
Perry asks us to discuss our reactions to some incidents of transphobia... by every definition have a certainly experienced transphobia, however recently i have begun a stance of non-participation in transphobic situations. i continue simply being. the reason people become trans has everything to do with genetics. there has, for nearly 40 or so years now, been scientifically validated evidence of a region of the brain that in the brains of male identifying individuals is shaped one way, and in female identifying individuals is shaped a different way. in other words science has discovered a part of the brain that determines gender. additionally there is a segment of the brain that determines sexual attractions and how or bodies react to different pheromones, which is not necessarily gender specific. for me knowing that down to my DNA i am a transsexual and resistance is futile is actually really comforting.From:TrannystarGalacticaViews:0 0ratingsTime:04:46More inEducation

Here is the original post:
TSG 217 - Transphobia, and the Non-Participation Option - Video

Recommendation and review posted by Bethany Smith

British scientists are to conduct the world's largest study of the genetics behind the lung condition chronic obstructive pulmonary disease (COPD).

Data from 50,000 individuals will be used to determine genetic variants linked to susceptibility to COPD.

In particular, researchers want to see how COPD genes relate to smoking, a major risk factor for the disease.

COPD comprises a group of disorders including chronic bronchitis and emphysema. Each year it affects around 900,000 people in the UK, causes 30,000 deaths, and costs the NHS 500 million.

Details of the new study are being released to mark World COPD Day.

The scientists will draw on the resources of the new UK Biobank, which holds genetic samples as well as health and lifestyle information on half a million volunteers.

Lead researcher Professor Ian Hall, dean of Nottingham Medical School, said: "We currently know very little about why there is such a wide difference in lung health even among smokers. It may have something to do with genetics so we're extremely excited about using the unique resource of the UK Biobank to test this theory."

The work is being funded by the Medical Research Council (MRC). Professor David Lomas, chair of the MRC Population and Systems Medicine Board, said: "We know that smoking is unhealthy for anyone but we know little about why the lungs of most smokers are seriously affected, while those of some seem to stay relatively healthy.

"If we knew more about the genetics that cause this variation we would be better able to direct treatments to those who are most at risk and have an increased chance of developing drugs to target this type of lung disease."

Scientists from the University of Nottingham, the University of Leicester, and St George's, University of London, are taking part in the research.

Read this article:
Genetics study into lung condition

Recommendation and review posted by Bethany Smith

WASHINGTON--(BUSINESS WIRE)--

Affordable and higher quality food will result from new genetic advances inspired by a unique industry collaboration. Two of the worlds largest animal breeding companies aim to achieve further breakthroughs in the field of genomics during the next three years of a joint development agreement (JDA).

Arkansas-based Cobb-Vantress Inc. and Hendrix Genetics B.V. which is headquartered in Boxmeer in the Netherlands initially set up the JDA in 2008 to share and promote expertise, particularly in the fast-growing field of genomics. Already new genomic selection tools have been discovered and developed, such as the cutting-edge SNP Chip for chickens. This is a glass slide that can analyze between 60,000 and 1 million variations in DNA sequences - or Single Nucleotide Polymorphisms (SNPs) - which act as biological markers and help scientists locate a range of genes associated with disease.

The extended agreement will intensify efforts to develop new tools and discover fresh insights into animal genomics in order to improve breeding programs and help increase world food production.

Dr. Gerard Albers, head of research and technology at Hendrix Genetics, said: This is like two renowned chefs sharing recipes, swapping thoughts and ideas on how to create a perfect dish. There are many ways to create this dish, many ingredients that can be used, and with shared views we are able to come closer to this perfect dish.

The collaboration is the biggest within the animal breeding industry and will produce animals that are more productive, less susceptible to disease and at reduced cost, therefore helping to tackle global food shortages. According to the United Nations World Food Program there are 870 million undernourished people in the world today.

The JDA will also strengthen Cobbs leading position in broiler breeding and Hendrix Genetics renowned role in layer hen, turkey, pig and aquaculture genetics, while enabling the two companies to further explore joint venture business opportunities.

Cobb-Vantress is the worlds leading supplier of broiler breeding stock and technical expertise for the chicken meat industry. It has about 2,500 employees and serves the industry in more than 90 countries.

Hendrix Genetics has nearly 2,400 employees worldwide and operations in 24 countries and provides expertise and resources to producers in more than 100 countries.

Jerry Moye, president of Cobb-Vantress, said: The joint efforts of the Hendrix and Cobb R&D teams have provided valuable knowledge for both of our companies. Cobb is excited to continue our partnership with Hendrix Genetics. We look forward to discovering what opportunities may be in our future.

Read the original here:
Lucid PR: COBB-VANTRESS AND HENDRIX GENETICS EXTEND R&D PARTNERSHIP

Recommendation and review posted by Bethany Smith

SEATTLE, WA--(Marketwire - Nov 14, 2012) - Atossa Genetics, Inc. ( NASDAQ : ATOS ) announced today the closing of its initial public offering of 800,000 shares of its common stock at an initial public offering price of $5.00 per share. Atossa Genetics' common stock is traded on the NASDAQ Capital Market under the trading symbol "ATOS."

Dawson James Securities, Inc. acted as the sole book-running manager and lead underwriter for this offering along with ViewTrade Securities, Inc. and Paulson Investment Company.

A copy of the final prospectus relating to the offering may be obtained by contacting Monique Maclaren of Dawson James Securities, Inc. at (561) 391-5555 or by emailing mmaclaren@dawsonjames.com or by standard mail at 925 S. Federal Highway, Suite 600, Boca Raton, FL 33432. You may also obtain these documents for free by visiting EDGAR on the SEC's website at http://www.sec.gov.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on November 7, 2012. This offering was made solely by means of a prospectus. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Atossa Genetics, Inc.

Atossa Genetics, Inc., The Breast Health Company, is based in Seattle, Washington, and is focused on the prevention of breast cancer through the commercialization of diagnostic medical devices and tests that can detect precursors to breast cancer, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

Go here to read the rest:
Atossa Genetics, Inc. Announces Closing of Initial Public Offering

Recommendation and review posted by Bethany Smith

WALTHAM, Mass.--(BUSINESS WIRE)--

Interleukin Genetics,Inc. (ILIU) today announced financial and operational results for the third quarter ended September 30, 2012.

Total revenue for the three months ended September 30, 2012 was $420,000, compared to $765,000 for the same period in the prior year. The decrease was primarily attributable to a decrease in genetic tests returned and processed and lower sales of our Inherent Health brand of genetic tests through our Merchant Network and Channel Partner Agreement with Amway Global. Cash received from genetic test sales is reflected as deferred revenue until the test report is issued. Deferred revenue increased $146,000 to $971,000 at September 30, 2012 as compared to December 31, 2011.

Research and development expenses were $246,000 for the three months ended September 30, 2012, compared to $325,000 for the same period in the prior year. The decrease was primarily attributable to lower consulting costs partially offset by increased compensation costs.

Selling, general, and administrative expenses were $1.0 million for the three months ended September 30, 2012, compared to $1.1 million for the same period in the prior year. The decrease was primarily attributable to lower patent related legal fees, insurance, consulting and sales commissions paid to Amway partially offset by increased professional fees and employee separation costs.

The Company reported a net loss of $1.3 million, or $(.03) per basic and diluted common share, for the third quarter of 2012 compared to $1.1 million, or $(.03) per basic and diluted common share, for the same period in 2011. On September 30, 2012, the Company had cash and cash equivalents of $2.5 million.

The Company expects that its current and anticipated financial resources are adequate to maintain current and planned operations at least through November 30, 2012, the due date of its credit facility with Pyxis Innovations, Inc., and through March 31, 2013 if the due date of the credit facility is extended. Management is in discussions with Pyxis to extend this due date. The Companys independent registered public accounting firm has included an explanatory paragraph in their opinion in connection with the 2011 audit, relating to the Company's ability to continue as a going concern.

We are encouraged by the positive top line results received from the University of Michigan study that employed our PST test. The results of the study should provide the evidence to support broader use of this test to both improve preventive dental care and favorably influence healthcare costs. We are now focused on ramping up the broad commercialization of our PST genetic test for improved management of dental patients, said Kenneth S. Kornman, Chief Executive Officer of Interleukin Genetics.

Conference Call and Webcast Information

Interleukin Genetics will host a live conference call and webcast today at 4:30 p.m. EST to review the Companys new business developments and third quarter financial results. To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 (international). The live webcast and replay access will be available on the Investors section of the Companys Website at: http://www.ilgenetics.com.

Read the original here:
Interleukin Genetics Reports Third Quarter 2012 Financial Results

Recommendation and review posted by Bethany Smith

SALT LAKE CITY, Nov. 15, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the Piper Jaffray Healthcare Conference, at 4:00 p.m. Eastern Time on Tuesday, November 27, 2012. The conference is being held at The New York Palace in New York, New York.

The presentation will be available to interested parties through a live webcast accessible on the investor relations section of Myriad's website at http://www.myriad.com.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com

Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-G

Read more:
Myriad Genetics to Present at the Piper Jaffray Healthcare Conference

Recommendation and review posted by Bethany Smith

Advocation against Gene Therapy
Antony Vorobyov ENG 111 NK Ms. Soares 11-14-2011From:Antony VorobyovViews:1 0ratingsTime:05:17More inFilm Animation

See more here:
Advocation against Gene Therapy - Video

Recommendation and review posted by Bethany Smith

Essentials Of Genomic And Personalized Medicine
ll4.me Essentials Of Genomic And Personalized Medicine Derived from the comprehensive two-volume set, Genomic and Personalized Medicine also edited by Drs. Willard and Ginsburg, this work serves the needs of the evolving population of scientists, researchers, practitioners and students that are embracing one of the most promising avenues for advances in diagnosis, prevention and treatment of human disease. From principles, methodology and translational approaches to genome discoveries and clinical applications, Essentials ofGenomic and Personalized Medicine will be a valuable resource for various professionals and students across medical disciplines, including human genetics and genomics, oncology, neuroscience, gene therapy, molecular medicine, pharmacology, and biomedical sciences. Updates with regard to diagnostic testing, pharmacogenetics, predicting disease susceptibility, and other important research components as well as chapters dedicated to cardiovascular disease, oncology, inflammatory disease, metabolic disease, neuropsychiatric disease, and infectious disease, present this book as an essential tool for a variety of professionals and students who are endeavouring into the developing the diverse and practical field of genomic and personalized medicine.* Full color throughout* Includes contributions on genetic counselling, ethical, legal/regulatory, and social issues related to the practice of genomic medicine from leaders in the field * Introductory chapter ...From:melissawatkins987Views:0 0ratingsTime:00:10More inPeople Blogs

See the original post here:
Essentials Of Genomic And Personalized Medicine - Video

Recommendation and review posted by Bethany Smith

Clinical Pharmacology: Current Topics And Case Studies
ll4.me Clinical Pharmacology: Current Topics And Case Studies 1. Introduction- The discipline of Clinical Pharmacology- Markus Mller; Professor of Clinical Pharmacology, Vienna, Austria- Example: EACPT position paper- Current issues in drug development- Markus Mller; Professor of Clinical Pharmacology, Vienna, Austria- Example: Pfizer- Current issues in drug regulation- Marcus Mllner / Hans Georg Eichler; Professor and Head, Austrian Medicines Agency AGES, Vienna, Austria / Professor and Senior Medical Officer, EMEA, London, UK- Example: EMEA - Current issues in drug reimbursement- Anna Bucsics; Medical Director, Austrian Board of Social Security Institutions- Example: comparative effectiveness - 2. Clinical Trials- Ethics of clinical research- Ernst Singer; Professor and Head, Ethics Committee, Medical University Vienna, Austria- Example: Nrnberg, Helsinki, Belmont- GCP, Scientific misconduct- Brigitte Blchl-Daum; Professor of Clinical Pharmacology, Vienna, Austria- Example: Tuskegee, Vioxx- Phases of drug development, first in man studies- Bernd Jilma; Professor of Clinical Pharmacology, Vienna, Austria- Example: Tegenero- Clinical trials interventional studies- Michael Wolzt; Professor of Internal Medicine, Vienna, Austria- Example: CAST- Clinical trials observational studies- Ch. Male / H. Herkner; Professor of Pediatrics, Vienna, Austria/ Professor of Internal Medicine, Vienna, Austria- Example: CDC "Outbreak"- Pharmacokinetics / Pharmacodynamics- Hartmut Derendorf ...From:meganhorne326Views:1 0ratingsTime:00:12More inPeople Blogs

Originally posted here:
Clinical Pharmacology: Current Topics And Case Studies - Video

Recommendation and review posted by Bethany Smith

Introduction To Molecular Medicine And Gene Therapy
ll4.me Introduction To Molecular Medicine And Gene Therapy EAN/ISBN : 9780471461043 Publisher(s): John Wiley Sons, Wiley Format: ePub/PDF Author(s): Kresina, Thomas F. EAN/ISBN : 9780471461043 Publisher(s): John Wiley Sons, Wiley Format: ePub/PDF Author(s): Kresina, Thomas F.From:Blancathompson7854Views:0 0ratingsTime:00:15More inPeople Blogs

Read this article:
Introduction To Molecular Medicine And Gene Therapy - Video

Recommendation and review posted by Bethany Smith

Textbook Of Hemophilia
ll4.me Textbook Of Hemophilia The only up-to-date definitive reference source on hemophiliaThis book is an invaluable resource that provides an overview of all aspects of the care of patients with haemophilia. Covering how to assess both bleeding children and adults, Haemophilia A and B, molecular basis of the disease, the role of factors in coagulation, epidemiology, pharmacokinetics, and treatment of inhibitors. There will also be a section on musculoskeletal aspects of haemophilia as well as newer developments such as gene therapy and rare bleeding disorders.Textbook of Hemophilia is ideal for:Trainees and residents in hematology Hematologists in practice Specialists working in thrombosis and hemostasis as well as transfusion medicineWhy Buy This Book?The only up-to-date definitive reference source on hemophiliaEssential for all those managing hemophilia patients Detailed guidance on assessment, diagnosis, management and treatment Advice for everyday clinical questions Edited by three of the world #39;s leading experts on hemophilia Publisher: Wiley-Blackwell Illustration: N Language: ENG Title: Textbook of Hemophilia Pages: 00400 (Encrypted PDF) On Sale: 2008-07-15 SKU-13/ISBN: 9781405127691 Category: Medical : Hematology The only up-to-date definitive reference source on hemophiliaThis book is an invaluable resource that provides an overview of all aspects of the care of patients with haemophilia.From:dorethalopez5478Views:0 0ratingsTime:00:12More inPeople Blogs

Read the rest here:
Textbook Of Hemophilia - Video

Recommendation and review posted by Bethany Smith

Hemophilia - Jeri Freedman
ll4.me Hemophilia - Jeri Freedman Cutting-edge scientific breakthroughs in treating hemophilia, including gene therapy and recombinant DNA technology, are described. Symptoms of the disease are also detailed, providing a clear picture of what it is like to live with this ?royal disease.?Author: Freedman, Jeri Publisher: Rosen Young Adult Illustration: N Language: ENG Title: Hemophilia Pages: 00064 (Encrypted PDF) On Sale: 2007-01-01 SKU-13/ISBN: 9781404206984 Category: Juvenile Nonfiction : General Cutting-edge scientific breakthroughs in treating hemophilia, including gene therapy and recombinant DNA technology, are described. Symptoms of the disease are also detailed, providing a clear pictur jeri freedman, juvenile nonfiction, generalFrom:lamarsmith9854Views:0 0ratingsTime:00:11More inPeople Blogs

Go here to see the original:
Hemophilia - Jeri Freedman - Video

Recommendation and review posted by Bethany Smith

New era medicine: Reversal of a family #39;s heart rhythm disorder
In a world first, Sydney researchers have used gene-based therapy to successfully reverse an inherited heart rhythm disorder in members of an entire family, some of whom had previously been told they had only months to live. This gene-therapy, practised as part of the new era of personalised medicine, achieved remarkable results. The research is published in the Journal of the American College of Cardiology. Rather than using conventional heart failure medicine, the researchers from the Victor Chang Cardiac Research Institute in Sydney, identified and treated the gene mutation that caused their heart rhythm disorder, dilated cardiomyopathy (DCM). Many patients with severe disease returned to full health within 6 months. Find out more about this research and the work of the Victor Chang Institute at http://www.victorchang.org.auFrom:VCCRIViews:30 0ratingsTime:02:42More inScience Technology

See the original post:
New era medicine: Reversal of a family's heart rhythm disorder - Video

Recommendation and review posted by Bethany Smith

Gene Therapy-2012 Opening Ceremony
Gene Therapy-2012 Opening CeremonyFrom:omicsvideosViews:0 0ratingsTime:01:23More inScience Technology

Go here to see the original:
Gene Therapy-2012 Opening Ceremony - Video

Recommendation and review posted by Bethany Smith

David Kekich - Stem Cell Therapy Breakthrough
Centagen is developing technology to help millions of people who suffer from chronic pain, disease and injury with an advanced form of adult stem cell therapy. For more information go to http://www.indiegogo.comFrom:CentagenViews:325 118ratingsTime:02:35More inScience Technology

See the original post here:
David Kekich - Stem Cell Therapy Breakthrough - Video

Recommendation and review posted by simmons

Stem Cell Therapy | Stem Cell Malaysia
stemcellmalaysia.com Stem cell therapy is a form of cell therapy that makes use of stem cells harvested from placenta for disease treatment. Stem cell therapy is also used for beauty, anti-aging and health rejuvenation purposes. The efficacy of stem cell therapy has been in practice for decades. Many rich and wealthy individuals and celebrities pay hefty price for stem cell therapy just to maintain youthfulness and vitality. For many severely ill-stricken people who have exhausted all means of conventional therapy look toward stem cell therapy for saving their condition and life. stemcellmalaysia.comFrom:stemcells2012Views:224 2ratingsTime:07:23More inHowto Style

Follow this link:
Stem Cell Therapy | Stem Cell Malaysia - Video

Recommendation and review posted by simmons

Brainco, Pioneering Personalized Medicine for Nervous System diseases
Development of novel and efficacious treatments for neurological diseases and psychiatric disorders: Schizophrenia, Major Depression and Multiple SclerosisFrom:braincobiopharmaViews:2 0ratingsTime:05:53More inScience Technology

Here is the original post:
Brainco, Pioneering Personalized Medicine for Nervous System diseases - Video

Recommendation and review posted by sam

What is Regulatory Science? (video-full version)
What is regulatory science? And what does it mean to you? Watch and learn at FDA Voice. For more information on regulatory science, see: Why You Should Care About Regulatory Science go.usa.gov Personalized Medicine Will Fit You Like a Glove go.usa.gov FDA Targets Drug Side Effects go.usa.gov Emerging Technology Embraces the Future go.usa.gov Scientists Working to Keep Foods Safe go.usa.govFrom:USFoodandDrugAdminViews:12 0ratingsTime:05:06More inEducation

Originally posted here:
What is Regulatory Science? (video-full version) - Video

Recommendation and review posted by sam

What is Regulatory Science? (video-short version)
What is regulatory science? And what does it mean to you? Watch and learn at FDA Voice. For more information on regulatory science, see: Why You Should Care About Regulatory Science go.usa.gov Personalized Medicine Will Fit You Like a Glove go.usa.gov FDA Targets Drug Side Effects go.usa.gov Emerging Technology Embraces the Future go.usa.gov Scientists Working to Keep Foods Safe go.usa.govFrom:USFoodandDrugAdminViews:9 0ratingsTime:01:17More inEducation

Here is the original post:
What is Regulatory Science? (video-short version) - Video

Recommendation and review posted by sam

ERIGO Rehabilitation Therapy
Kalamata Rehabilitation Hospital, Erigo, Stroke, Traumatic Brain Injury, Spinal cord Injury, Stroke rehabilitation, Greek medical tourism, Kalamata,From:DiaplasisKalamataViews:5 0ratingsTime:00:33More inScience Technology

Link:
ERIGO Rehabilitation Therapy - Video

Recommendation and review posted by sam

The Spinal Cord Injury Program at Burke Rehabilitation Hospital
The goal of Burke Rehabilitation #39;s Spinal Cord Injury Program is to provide the most comprehensive and effective rehabilitation to maximize recovery from physical and psychological impairments caused by traumatic and non-traumatic spinal cord injuries. http://www.burke.org The multidisciplinary team works collaboratively with the individual with the spinal cord injury and the family and/or caregivers to facilitate achievement of the best possible physical and mental recovery. Program Goals Preparing the individual, family or caregiver for transition to the next stage of the rehabilitation process. Providing the highest quality, patient-focused rehabilitation, through an interdisciplinary approach based on communication, collaboration and cooperation. Establish an optimal model for patient centered, cost effective, interdisciplinary rehabilitative care of the individual whit a spinal cord injury. Team Composition Individual with spinal cord injury or disease Individual #39;s family and caregivers Neuropsychology Nutrition Occupational Therapy Physical Therapy Physician Recreation Therapy Rehabilitation Nursing Respiratory Therapy Social Work/Case Management Speech and Language Therapy Patients Served Paraplegia Tetraplegia Spinal Tumors Spinal Surgeries Multiple Sclerosis Guillain Barre Syndrome Neuromuscular Disorders Parkinsons Disease Equipment Enhancements LiteGait Bioness H200 and L300+ Motomed RT 300 FES Cycle WalkAide Zero G Light Bladder Scanners Patient Lifts Saeboflex Wii ...From:Burke785Views:0 0ratingsTime:01:27More inEducation

Continue reading here:
The Spinal Cord Injury Program at Burke Rehabilitation Hospital - Video

Recommendation and review posted by sam

Chris - Spinal Cord Injury Awareness Week.mov
From:BrooksHealthViews:3 0ratingsTime:02:50More inEducation

Read more from the original source:
Chris - Spinal Cord Injury Awareness Week.mov - Video

Recommendation and review posted by sam

Channel Ten News at Walk On - Discuss Better Start Funding 14.11.12.flv
Channel Ten news visit our Walk On Sydney Gym to meet Claire and her son Evander, who has a spinal cord injury. The story highlights the need to include children affected by paraplegia or quadriplegia in the Better Start funding.From:SpinalCordInjuriesAuViews:0 0ratingsTime:01:59More inNonprofits Activism

More:
Channel Ten News at Walk On - Discuss Better Start Funding 14.11.12.flv - Video

Recommendation and review posted by sam

Byrd Aesthetic and Anti-Aging Center CoolSculpting Commerical
http://www.byrdaesthetic.com CoolSculpting trade; is cleared by the FDA for the non-invasive reduction of fat. This procedure is a clinically proven method for the selective reduction of body fat. The unwanted fat cells are gently cooled inducing a natural, controlled elimination. Results are permanent. Dr. Marcia Byrd of the Byrd Aesthetic and Anti-Aging Center is located in Atlanta, Georgia. She is board-certified by the American Board of Laser Surgery and the American Board of Anti-Aging and Regenerative Medicine. For more information about CoolSculpting trade; and losing unwanted fat, call Dr. Byrd #39;s office toll free at 1.866.671.5633.From:DefinitiveMedicalViews:1 0ratingsTime:00:31More inScience Technology

More here:
Byrd Aesthetic and Anti-Aging Center CoolSculpting Commerical - Video

Recommendation and review posted by sam